NeoGenomics to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
The presentation will be webcast live and accessible online via this link. A replay will be available on the Investor Relations section of the Company’s website at ir.neogenomics.com.
About
Headquartered in
Forward-Looking Statements
This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “plan,” “potential” and other words of similar meaning, although not all forward-looking statements include these words. This press release includes forward-looking statements. These forward-looking statements address various matters, including statements regarding improving operational efficiency, returning to profitable growth and its ongoing executive recruitment process. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the Company's ability to identify and implement appropriate financial and operational initiatives to improve performance, to identify and recruit executive candidates, to continue gaining new customers, offer new types of tests, integrate its acquisitions and otherwise implement its business plan, and the risks identified under the heading "Risk Factors" contained in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company's other filings with the
We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240829956644/en/
Investor Contact
kendra.sweeney@neogenomics.com
Media Contact
asampson@sampsonprgroup.com
Source: